Skip to main content
. 2022 Jan 17;11:e69511. doi: 10.7554/eLife.69511

Figure 5. Deletion of ORF3 decreases the SOS response induction, after tobramycin treatment and ORF4 regulates the Hmp nitric oxide detoxification pathway.

(A) Relative expression of sulA in E. coli MG1656 (WT) derived isogenic strains carrying pDIJ09-518a with ORF3 and/or ORF4 deleted and complemented, exposed to mitomycin C (dark blue) or tobramycin (brown) in comparison to expression in lysogeny broth (LB), normalized with dxs. Data represent median values of six independent biological replicates, and error bars indicate upper/lower values. *p < 0.05. Wilcoxon matched-pairs signed-rank test. (B) Nitric oxide (NO) formation for the isogenic strains (n = 6). Data were analysed using a Kruskal–Wallis test, with a p value <0.0001 for the overall analysis of variance (ANOVA). NO formation for each strain was analysed using Dunn’s multiple comparisons test. *p < 0.05, **p < 0.01, and ***p < 0.001. Bars represent mean values and SD. (C) Relative expression of hmp in E. coli MG1656 (WT) derivative isogenic strains carrying pDIJ09-518a with ORF3 and/or ORF4 deleted and complemented, or the empty vector, grown in LB, in comparison to expression in E. coli MG1656 (WT), normalized with dxs. Data represent median values of six independent biological replicates, and error bars indicate upper/lower values. Wilcoxon matched-pairs signed-rank test. *p < 0.05.

Figure 5—source data 1. Relative expression of sulA in E. coli MG1656 (WT) derived isogenic strains #1.
Figure 5—source data 2. Relative expression of sulA in E. coli MG1656 (WT) derived isogenic strains #2.
Figure 5—source data 3. Relative expression of sulA in E. coli MG1656 (WT) derived isogenic strains #3.
Figure 5—source data 4. DAF-2A fluorescence in E. coli MG1656 (WT) and complemented strains.
Figure 5—source data 5. Relative expression of hmp in E. coli MG1656 (WT) and isogenic strains.

Figure 5.

Figure 5—figure supplement 1. Spontaneous mutation ratio after treatment with sub-minimum inhibitory concentration (MIC) of tobramycin.

Figure 5—figure supplement 1.

Bacteria were grown overnight in lysogeny broth (LB) supplemented or not with sub-MIC of tobramycin (0.001 µg/ml). Appropriate dilutions were plated on LB plate, and 1 ml of culture was centrifuged and plated on 200 μg/ml rifampin plates. The y-axis shows the ratio of the spontaneous mutations to rifampicin resistance correspond to the rifampin-resistant colony-forming unit (CFU) count over the total number of CFU in the presence or in the absence of sub-MIC of tobramycin. Error bars represent standard deviation (of the median). Two independent experiments with six independent cultures each were used. Results are shown as the average frequencies of all 12 cultures. ***p < 0.010. Wilcoxon matched-pairs signed-rank test.
Figure 5—figure supplement 1—source data 1. CFU counting after treatment of sub-MIC of tobramycin.